



## MATERIAL SAFETY DATA SHEET

**Product Name: Tazicef® (Ceftazidime for Injection, USP)**

### 1. CHEMICAL PRODUCT AND COMPANY INFORMATION

**Distributor Name  
And Address** Hospira, Inc.  
275 North Field Drive  
Lake Forest, Illinois 60045  
USA

**Emergency Telephone  
Hospira, Inc.** CHEMTREC: 800 424-9300  
224 212-2055

**Manufacturer Name  
And Address** Sandoz GmbH  
Biochemiestrasse. 10  
A-6250 Kundl, / Tirol  
Austria

**Product Name** Tazicef® (Ceftazidime for Injection, USP)

**Synonyms** None

### 2. COMPOSITION/INFORMATION ON INGREDIENTS

**Ingredient Name** Ceftazidime pentahydrate  
**Chemical Formula**  $C_{22}H_{32}N_6O_{12}S_2$

Component	Approximate Percent by Weight	CAS Number	RTECS Number
Ceftazidime pentahydrate	90	78439-06-2	NA
Sodium bicarbonate	10	144-55-8	NA

### 3. HAZARD INFORMATION

**Emergency Overview** In clinical use, this material is used as an antibiotic to treat infection. May cause sensitization by inhalation and skin contact. Ceftazidime may cause severe allergic reactions.

**Occupational Exposure  
Potential** Information on the absorption of this compound via ingestion, inhalation or skin contact is not available. Workplace overexposure may include symptoms of hypersensitivity such as rash, itching, difficulty breathing, nausea, or diarrhea.

**Signs and Symptoms** Data on this class of compound (cephalosporins) suggest the following: allergic reaction, eye irritation, rash, itching, difficulty breathing, nausea, or anaphylactic shock.

**Medical Conditions  
Aggravated by Exposure** Hypersensitivity to penicillin or cephalosporin compounds.

**Product Name: Tazicef® (Ceftazidime for Injection, USP)**

**4. FIRST AID MEASURES**

<b>Eye Contact:</b>	Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.
<b>Skin Contact:</b>	Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.
<b>Inhalation:</b>	Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic / supportive care as necessary.
<b>Ingestion:</b>	Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic / supportive care as necessary.

**5. FIRE FIGHTING MEASURES**

<b>Flammability:</b>	Non-flammable
<b>Fire &amp; Explosion Hazard:</b>	Powders dispersed in air and subjected to an ignition source could explode.
<b>Extinguishing Media:</b>	Use extinguishing media appropriate for primary cause of fire.
<b>Special Fire Fighting Procedures</b>	No special provisions required beyond normal fire fighting equipment such as flame and chemical resistant clothing and self contained breathing apparatus.

**6. ACCIDENTAL RELEASE MEASURES**

<b>Spill Cleanup and Disposal</b>	Collect spilled powder using techniques that minimize powder migration. Clean affected area with soap and water. Dispose of materials according to the applicable federal, state, or local regulations.
-----------------------------------	---

**7. HANDLING AND STORAGE**

<b>Handling</b>	No special handling required.
<b>Storage</b>	No special storage required for hazard control. For product protection store at controlled room temperature of 20-25°C (68-77°F).
<b>Special Precautions</b>	No special precautions related to hazard control.

**Product Name: Tazicef® (Ceftazidime for Injection, USP)**

**8. EXPOSURE CONTROLS/PERSONAL PROTECTION**

<b>Exposure Guidelines</b>	None established.
<b>Respiratory Protection</b>	Respiratory protection is not needed during normal product use. Should powder inhalation be an exposure risk use of an approved respirator would be prudent practice.
<b>Skin Protection</b>	If contact with unprotected skin is likely, glove use is prudent practice.
<b>Eye Protection</b>	Eye protection is not required during expected product use conditions but may be warranted if eye contact is likely.
<b>Engineering Controls</b>	Engineering controls are not needed during normal product use conditions.

**9. PHYSICAL/CHEMICAL PROPERTIES**

<b>Appearance/Physical State</b>	White to slight yellow powder
<b>Odor</b>	Not Determined
<b>Boiling Point</b>	Not Determined
<b>Freezing Point</b>	Not Determined
<b>Vapor Pressure</b>	Not Determined
<b>Vapor Density (Air=1)</b>	Not Applicable
<b>Evaporation Rate</b>	Not Applicable
<b>Bulk Density</b>	Not Determined
<b>Specific Gravity</b>	Not Determined
<b>Solubility</b>	Water: 30 g/l, 25 degrees C
<b>pH</b>	Not Determined

**10. STABILITY AND REACTIVITY**

<b>Chemical Stability</b>	Stable under standard use and storage conditions.
<b>Incompatibilities</b>	May react with strong oxidizing agents.
<b>Hazardous Decomposition Products</b>	May emit toxic smoke.
<b>Hazardous Polymerization</b>	Will not occur.

**11. TOXICOLOGICAL INFORMATION:**

**Acute Toxicity – Oral:**

<b>Ingredient(s)</b>	<b>Percent</b>	<b>Test Type</b>	<b>Value</b>	<b>Units</b>	<b>Species</b>
Ceftazidime	100	LD50	>2000	mg/kg	Rats

LD50 is dosage producing 50% mortality.

Product contains approximately 90% Ceftazidime.

**Mutagenicity** Not mutagenic in bacterial or mammalian cells.

**Reproductive Effects** No effects identified.

**Product Name: Tazicef® (Ceftazidime for Injection, USP)**

**Target Organ Effects**                      Blood effects include decreased red blood cell count and increased white blood cell count. Other target organs include liver and kidneys.

**12. ECOLOGICAL INFORMATION:**

**Aquatic Toxicity**                      Not Available

**13. DISPOSAL CONSIDERATIONS:**

**Waste Disposal**                      Disposal should be performed in accordance with the federal, state or local regulatory requirements.

**Container Handling and Disposal**                      Dispose of container and unused contents in accordance with federal, state, and local regulations.

**14. TRANSPORTATION INFORMATION**

**DOT**    Not Regulated

Notes:    DOT - US Department of Transportation Regulations

**15. REGULATORY INFORMATION**

**TSCA Status**                                      Not Regulated  
**CERCLA Status**                                      Not Regulated  
**SARA Status**                                        Not Regulated  
**RCRA Status**                                        Not Regulated  
**PROP 65 (Calif.)**                                      Not Regulated

Notes:    TSCA Toxic Substance Control Act  
            CERCLA, US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act  
            SARA Superfund Amendments and Reauthorization Act  
            RCRA US EPA, Resource Conservation and Recovery Act  
            Prop 65, California Proposition 65

**16. OTHER INFORMATION:**

**MSDS Coordinator**                      Global Occupational Toxicology  
**Date Prepared**                                      September 15, 2005  
**Date Revised**                                        October 21, 2008

**Disclaimer:**

The information and recommendations contained herein are based upon tests believed to be reliable. However, Hospira does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. Hospira assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.